PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Methylnaltrexone→

Methylnaltrexone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
83387-25-1
Molecular formula
C21H26NO4+
Molecular weight
356.4 g/mol
Drug class
Opioid Antagonist
Mechanism of action
Opioid Antagonists
Indications / reported uses
  • Constipation
  • opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
  • OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care
  • opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
  • OIC in adult patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Methylnaltrexone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Methylnaltrexone Permitted Daily Exposure (PDE) report (the Methylnaltrexone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Methylnaltrexone Occupational Exposure Limit (OEL) report (the Methylnaltrexone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.